Lessons learned from the 2024 External Quality Assessment (EQA) scheme for molecular testing in Lung (NSCLC) cancer tissue samples.

The EQA scheme for molecular testing in non-small cell lung cancer (NSCLC) in tissue has been running for 14 years and currently has a global participation of 350 laboratories in 32 countries. In 2024 it comprised two sub-schemes:
• Mandatory testing for common biomarkers (CB) in the EGFR, KRAS and BRAF genes
• Optional testing for new and emerging biomarkers (NEB) in the EGFR, KRAS, ERBB2 and MET genes

This White Paper shares valuable lessons learned from the 2024 worldwide EQA scheme for molecular testing in NSCLC